Video

Dr. Matulonis on CPS as a Potential Biomarker in Advanced Recurrent Ovarian Cancer

Ursula A. Matulonis, MD, discusses the potential role of combined positive score as a biomarker in advanced recurrent ovarian cancer.

Ursula A. Matulonis, MD, a professor of medicine at Harvard Medical School, as well as a medical oncologist and chief of the Division of Gynecologic Oncology of the Susan F. Smith Center for Women's Cancers at Dana-Farber Cancer Institute, discusses the potential role of combined positive score (CPS) as a biomarker in advanced recurrent ovarian cancer.

The results from the KEYNOTE-100 trial demonstrated modest clinical activity with pembrolizumab (Keytruda), and a trend toward increased overall response rate with higher PD-L1 expression was observed in both cohorts analyzed. Now that results from the KEYNOTE-100 trial have been read-out, the company that sponsored the trial should be asked what they are going to do with these data, says Matulonis. Obviously, clinicians can do what they like with these data, especially in a patient who is heavily pretreated, says Matulonis.

However, oncologists need to make sure that the pathologist they are working with generates a PD-L1 expression score by this CPS, because it was the way that PD-L1 expression levels were measured and read-out on this trial, explains Matulonis. The trial was not simply looking at PD-L1 expression of the cancer cells, concludes Matulonis.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Addressing Unmet Needs in HER2+ Metastatic BTC
Video

Addressing Unmet Needs in HER2+ Metastatic BTC

Apr 18th 2025 - Apr 19th 2026

online-activity
Community Oncology Connections™: Case Discussions in TNBC…Navigating the Latest Advances and Impact of Disparities in Care | North Carolina
Video

Community Oncology Connections™: Case Discussions in TNBC…Navigating the Latest Advances and Impact of Disparities in Care | North Carolina

Apr 17th 2025 - May 23rd 2025

online-activity
Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Minnesota
Video

Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Minnesota

Apr 17th 2025 - May 23rd 2025

online-activity